AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02661061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: A sub-anaesthetic dose of midazolam will be administered in four infusions, each two weeks apart.
Study NCT03292614 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurements of the postoperative refraction
Description: The Measurements of the postoperative refraction will be performed with the following devices:~Autorefractor Keratometers:~Mod. ARK-760A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany), Mod. ARK-560A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany) KR-1W (TOPCON, Willich, Germany) KR-800s (TOPCON, Willich, Germany)~Manual Refractometer:~Eye refractometer PR 60 or PR 50 (Rodenstock, Munich),~Test device:~iTrace (TraceyTechnologies, Houston, Texas, USA),~Phoropter (Block-Optic, Model 11625B) Determination of subjective refraction for distance and near (reading distance)
Study NCT02242019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia LUNULA
Description: The Erchonia LUNULA is administered to the infected toes for 12 minutes per treatment for 4 treatments, each treatment one week apart.
Study NCT00559143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular Pacing (DDD(R)- BiV)
Description: Subjects indicated for DDD(R) pacing due to AV conduction disturbances and preserved LV function will receive biventricular pacing DDD(R)- BiV
Study NCT00559143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biventricular Pacing (DDD(R)- BiV)
Description: Subjects indicated for DDD(R) pacing due to AV conduction disturbances and preserved LV function will receive biventricular pacing DDD(R)- BiV
Study NCT02394119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 1500 mg/1.73m2, administered once diluted in 1000 ml of normal saline
Study NCT02394119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2, administered once diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg.
Study NCT02371876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ONYX PLUS Investigational Blood Glucose Monitoring System
Description: Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX PLUS Investigational Blood Glucose Monitoring System. All BG results were compared to reference method results obtained from subject capillary blood. Study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
Study NCT00532727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 every 3 weeks for six cycles (18 weeks)
Study NCT00532727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 100mg/m2 every 3 weeks for six cycles (18 weeks)
Study NCT02168777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refametinib (BAY86-9766)
Description: Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used.
Study NCT02168777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 1b dose escalation, regorafenib will be administered in a 3-weeks-on / 1-week-off schedule except in one cohort, that uses regorafenib 2 weeks on / 2 weeks off regimen (dose level -2). In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used.
Study NCT03307837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: Local administration during surgery
Study NCT03307837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Local administration during surgery
Study NCT01744483 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVC ETT
Description: Placement of a PVC-cuffed ETT in the setting of emergent intubation.
Study NCT01744483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PUC ETT
Description: Placement of a PUC-cuffed ETT in the setting of emergent intubation.
Study NCT01744483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PUC-CASS ETT
Description: Placement of a PUC-cuffed in the setting of emergent intubation, followed by continuous aspiration of subglottic secretions for the duration of mechanical ventilation.
Study NCT00708474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoFit™ Porous Tissue Matrix™
Description: Bone void filler
Study NCT01569698 — intervention group
Intervention type: PROCEDURE
Intervention: acute extra renal replacement therapy
Description: usual modalities of pediatric acute extra renal replacement therapy : Intermittent Hemodialysis, Continuous Renal Replacement Therapies, and Peritoneal Dialysis
Study NCT02800915 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Service innovation with focus on multidisciplinary collaboration
Description: The follow-up is performed via telemedicine (videoconference) to the patient in his or her own home, and in cooperation with the district nurses.
Study NCT02800915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Service innovation with focus on multidisciplinary collaboration
Description: The follow-up is performed via telemedicine (videoconference) to the patient in his or her own home, and in cooperation with the district nurses.
Study NCT00428012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Therapy
Description: 8 weekly individual counseling sessions
Study NCT00428012 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: 8 weekly individual counseling sessions
Study NCT02461056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Drug was administered by the Dixon and Mood up-and-down method. Starting doses was ibuprofen 50 mg. The maximum doses was ibuprofen 800 mg. Combination index (CI) (additive: 0.9-1.1, synergism: \<0.9, antagonism: >1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
Study NCT02306590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03968068 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Procedure
Description: Patients will undergo 30 minutes of light-moderate intensity leg cycling, using the Letto-2 (Motomed, UK) in the semi-supine position.
Study NCT03968068 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Conditioning
Description: Patients will undergo 4 cycles of upper limb RIC using a blood pressure cuff. Each cycle will involve inflating the blood pressure cuff to 200 mmHg for five minutes around the upper arm, followed by a period of relaxation of the cuff for a further 5 minutes. The total RIC treatment time will take 40 minutes.
Study NCT03967912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE UP
Description: Each of the 12 group sessions will focus on incremental behavioral strategies for maintaining healthy eating, activity, and weight loss.behaviors. Body weight will be measured in-person session and participants will also to measure their body weight on their in Session 3, participants are given physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (\<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; >250 pounds = 1800 kcal/d).
Study NCT01531101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual psychodynamic psychotherapy
Description: Individual psychodynamic psychotherapy with or without transference work. I.e. with or without relational therapist interventions focusing on the patient-therapist relationship.
Study NCT01531101 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual psychodynamic psychotherapy
Description: Individual psychodynamic psychotherapy with or without transference work. I.e. with or without relational therapist interventions focusing on the patient-therapist relationship.
Study NCT03924115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transmedial Psychoeducational Program to improve adherence full or partial (PS)
Description: Intervention consists of a transmedial Psychoeducational Program, which includes cognitive, behavioral and affective aspects to generate knowledge and skills that improve self-efficacy in the elderly, it is a program based on communication in health. The proposed transmedial narrative will allow older adults to assemble information from messages arranged through various media, including audiovisual capsules that will be transmitted on screens located in the Health Center and the development of a mobile application incorporated in the cellular that will be delivered with a data plan for one year. This intervention is designed to strengthen the personal resources of the elderly (such as self-efficacy, empowerment, knowledge) that promote self-care in health.
Study NCT04537598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Morphine patient controlled analgesia
Description: 30 patients will receive PCA only for postoperative analgesia
Study NCT04537598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae plane block
Description: 30 patients will receive continuous ESPB for postoperative analgesia
Study NCT02977286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol Oral Tablet
Description: Naloxegol Oral Tablet 25 mg (or 12.5 mg) po (enteral) daily
Study NCT02977286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet po (enteral) twice daily
Study NCT02977286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docusate Sodium 100 Mg oral capsule [Colace]
Description: Docusate Sodium 100 mg po (enteral) twice daily
Study NCT02977286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docusate Sodium 100 Mg oral capsule [Colace]
Description: Docusate Sodium 100 mg po (enteral) twice daily
Study NCT02977286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senna 217 Mg Oral Tablet
Description: Senna 127 mg oral tablet daily if no spontaneous bowel movement >/=3 days after scheduled opioid initiation; increase to two senna 127 mg tables if no no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement >/=5 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement >/=6 days after scheduled opioid initiation.
Study NCT02977286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Senna 217 Mg Oral Tablet
Description: Senna 127 mg oral tablet daily if no spontaneous bowel movement >/=3 days after scheduled opioid initiation; increase to two senna 127 mg tables if no no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement >/=5 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement >/=6 days after scheduled opioid initiation.
Study NCT02977286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycols
Description: Polyethylene Glycols 17 g daily if no spontaneous bowel movement >/=3 days after scheduled opioid initiation; increase to 34 g daily if no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation.
Study NCT02977286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polyethylene Glycols
Description: Polyethylene Glycols 17 g daily if no spontaneous bowel movement >/=3 days after scheduled opioid initiation; increase to 34 g daily if no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation.
Study NCT02977286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl 10 mg Suppository
Description: Insert one suppository if no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation.
Study NCT02977286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bisacodyl 10 mg Suppository
Description: Insert one suppository if no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation.
Study NCT02977286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Citrate Oral Liquid Product
Description: Administer one 10 oz bottle if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation.
Study NCT02977286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium Citrate Oral Liquid Product
Description: Administer one 10 oz bottle if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation.
Study NCT02977286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Administer 8 mg or 16 mg (depending on subject's weight) subcutaneously x 1 if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation, consult surgery/gastroenterology and discontinue study medication.
Study NCT02977286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylnaltrexone
Description: Administer 8 mg or 16 mg (depending on subject's weight) subcutaneously x 1 if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation, consult surgery/gastroenterology and discontinue study medication.
Study NCT04426435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: honey based (HB) syrup
Description: honey-based syrup is prepared according to the documented Persian Medicine manuscripts with some modifications. HB is a mixture of honey, rose water and saffron. Each 100g of HB consisted of 79.87 g honey, 19.97 g rose water, and 0.16 g saffron.~All the ingredients were licensed and approved by The Islamic Republic of Iran Food and Drug Organization (I.R.I.FDO).
Study NCT04426435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: honey based (HB) syrup
Description: honey-based syrup is prepared according to the documented Persian Medicine manuscripts with some modifications. HB is a mixture of honey, rose water and saffron. Each 100g of HB consisted of 79.87 g honey, 19.97 g rose water, and 0.16 g saffron.~All the ingredients were licensed and approved by The Islamic Republic of Iran Food and Drug Organization (I.R.I.FDO).
Study NCT04192864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lingually based triangular flap
Description: A lingually based triangular flap was used to remove the impacted third molar. An incision was made adjacent to the distal surface of the mandibular second molar and extended along the sulcus to the distobuccal corner of the mandibular second molar, an oblique vestibular incision was made and extended into the vestibular fornix of the mandible. Aligned with the mesiobuccal cusp of the second molar.~It was continued posterosuperior towards the anterior border of the mandibular ramus An incision will be made from the anterior border of the mandibular ramus to the distal surface of the mandibular second molar.
Study NCT04192864 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccally based triangular flap
Description: The impacted teeth was removed using a buccal based triangular flap. It will be extended along the sulcus to the distobuccal corner of the second molar . The incision was continuous, with a relieving vertical incision, oblique into the mandibular vestibular fornix, aligned with the mesiobuccal cusp of the second molar.
Study NCT02264262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiologic maneuvers
Description: Subjects will perform cold pressor test, valsalva maneuver, hand grip and post-exercise occlusion in a controlled research environment
Study NCT02484989 — intervention group
Intervention type: OTHER
Intervention: Surviellance card
Study NCT01013142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-221 (Dose Group 1)
Description: i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour
Study NCT01013142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MN-221 (Dose Group 1)
Description: i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour
Study NCT01013142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-221 (Dose Group 2)
Description: i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour
Study NCT01013142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MN-221 (Dose Group 2)
Description: i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour
Study NCT02461056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Drug was administered by the Dixon and Mood up-and-down method. Starting doses was hydromorphone 0.25 mg. The maximum doses was hydromorphone 2 mg. Combination index (CI) (additive: 0.9-1.1, synergism: \<0.9, antagonism: >1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
Study NCT03236129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-reg depleted DLI
Description: The patients in the experimental arm benefit of a DLI depleted from regulatory T lymphocytes
Study NCT03236129 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard DLI
Description: The patients in this arm benefit of a standard DLI.
Study NCT04428528 — intervention group
Intervention type: DEVICE
Intervention: Photoacoustics Imaging System
Description: Characterizing breast masses for photoacoustic markers measurements
Study NCT01013142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-221 (Dose Group 3)
Description: i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour
Study NCT01013142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MN-221 (Dose Group 3)
Description: i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour
Study NCT03325777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach Bias Retraining
Description: The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
Study NCT03325777 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: SHAM Training
Description: SHAM Training
Study NCT01238536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural steroid with local anesthetic injection
Description: Epidural steroid injectate will be 2cc of 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
Study NCT01238536 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural local anesthetic injection
Description: Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
Study NCT01238536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection
Description: Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
Study NCT01238536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural local anesthetic injection
Description: Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
Study NCT03482752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim
Description: 300 µg inhaled molgramostim in cycles of once daily administration for 7 days, then 7 days off treatment.
Study NCT01883284 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tests in vitro after sampling nasal cells of CF patients or controls
Description: Nasal cells of CF patients or controls were collected by scratching of intermediate turbinate and cultured in vitro. Epigenetic modifiers treatment was applied to these ex vivo nasal epithelia. Then, mRNA, protein and secretions were quantified.